Might oral zinc protect pancreatic B-cells against oxidative insults?
Failla
Mark L
ML
D000284:Administration, Oral; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000517:prevention & control*; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control*; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D015032:Zinc / Q000008:administration & dosage*
D016328:NF-kappa B; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D015032:Zinc